Intravascular clot formation is a serious event which leads to a number of ischemic diseases, such as myocardial infarction, stroke and venous thromboembolism. At present, warfarin is the sole oral anticoagulant that is being widely used for prophylaxis and treatment of thrombosis. However, many reports have mentioned the limitations of warfarin. [2] [3] [4] Indeed, warfarin requires frequent international normalized ratio (INR) monitoring because of its narrow therapeutic window and the large inter-and intraindividual variability in its effect. In addition, its onset of anticoagulant action is considerably slow and it interacts with many foods and conventional agents. Accordingly, novel oral anticoagulants with high efficacy and without INR monitoring are desired.
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Factor Xa (FXa) has been thought of as a particularly promising target for effective anticoagulation because it acts at the convergence point of the intrinsic and extrinsic coagulation pathways. Moreover, one molecule of FXa generates more than 100 thrombin molecules. 5) It is thought that inhibition of FXa effectively blocks thrombin formation, thereby diminishing thrombin-mediated fibrin clot formation. Recent research has focused on the identification of orally available small-molecule FXa inhibitors that do not require routine coagulation monitoring. 6, 7) In a previous paper, we reported that compound (R)-1 ( Fig.  1) , which has the (R)-configuration at the 2-position of the indoline ring, showed potent inhibitory activity against FXa in vitro. 8) However, orally administered (RS)-1 had high toxicity in mice. We intended to explore new indoline compounds with potent FXa inhibitory activity and diminished that for 8a-g. Then, intermediate 13 was introduced to a trimethylsilylmethyl group to give two regioisomers (14, 15) 12) which were separable from each other by using silica gel column chromatography. 13) These two compounds (14, 15) were coupled with 2-cyano-7-naphthylaldehyde (16) 14) by tetrabutylammonium fluoride (TBAF), followed by reduction of the nitro group by catalytic hydrogenation to give anilines 17 and 18, respectively. By the same method as described in Charts 1 and 2, anilines 17 and 18 were converted to corresponding compounds 21 and 22, which have 4 and 6-substituted indoline structures, respectively.
Indoline Derivatives II: Synthesis and Factor Xa (FXa) Inhibitory Activities
5-Alkyl or 5-(methyl)aminoindoline derivatives (27, 33) were synthesized as shown in Chart 4. 5-Hydroxyindoline compound (23) 8) was converted to its trifluoromethanesulfonate 24. 15) This compound was subjected to a SuzukiMiyaura cross coupling reaction 16, 17) with N-Boc-4-methyl-enepiperidine (25) 18) to give compound 26, which has a methylene chain between the indoline ring and piperidine ring. By the same method as described in Chart 2, compound 26 was converted to corresponding 5-alkylindoline derivative 27. Regarding the 5-(methyl)aminoindoline derivative, 19) 4-fluoro-1-nitrobenzene (28) was reacted with N-Boc-4-aminopiperidine (29) under basic conditions, followed by the introduction of a methyl group on the nitrogen atom to give intermediate 31. Compound 31 was converted to the corresponding 5-(methyl)aminoindoline derivative 33 by the same procedures as described in Charts 1 and 2.
The effective and practical synthesis of enantiomerically pure intermediate (S)-3 without using chiral column chromatography is outlined in Chart 5. Racemate 2 was reacted with (S)-O-acetylmandel chloride 20) to give mandelate 34 as a diastereomixture. The diastereomixture was subjected to crystallization (solvent: EtOAc/Et 2 Oϭ1/20) to give optically pure mandelate (S)-34 having an S-configuration. Furthermore, to provide more (S)-34 we attempted to perform a stereochemical inversion of the diastereomixture containing mainly (R)-34, rather than (S)-34 in the filtrate. The diastereomixture given from the filtrate was subjected to alcohol hydrolysis under basic conditions and a subsequent Mitsunobu reaction with (S)-O-acetylmandelic acid afforded the diastereomixture containing (S)-34. The diastereomixture was subjected to crystallization (solvent: Et 2 O) to achieve an additional synthesis of mandelate (S)-34. After alcohol hydrolysis of mandelate (S)-34, the nitro group was reduced to give enantiomerically pure (>99% ee) alcohol (S)-3. At this point, we had succeeded in a multi-gram (ca. 10 g) synthesis of (S)-3. Therefore, we considered that this synthetic route was applicable to the scale-up synthesis of (S)-3. The stereochemistry of (S)-3 was confirmed by a comparison with the same compound reported in the previous paper. 21) After the reaction of (S)-3 with ethyl chlorosulfonylacetate, 22) stereochemically inversed intermediate (R)-8d was obtained according to the same procedure as that for 8d. Optically active bisamidine (R)-10d was synthesized from (R)-8d by the same method as described in Chart 2. Moreover, carboxylic acid (R)-11d was synthesized by the acidic hydrolysis of (R)-10d.
Results and Discussion
The in vitro FXa inhibitory activities of all the compounds synthesized were evaluated and expressed as IC 50 values. Based on the results of our previous report, we attempted further optimization for each moiety of our indoline derivative. At first, we compared the effects of the position and the linker atom of the piperidine ring to racemate (RS)-1 (Table  1) . Regarding for the substitution pattern of the central indoline ring, 5-substituted indoline compound (RS)-1 showed higher FXa inhibitory activity than 4-substituted one 21 and 6-substituted one 22. In these three regioisomers, it seemed that 5-substituted compound is more favorable than the other two compounds. Regarding the linker structure of 5-substituted indoline compounds, we synthesized compounds having a methylene group (27) or methylamino group (33) instead of an oxygen atom. Although both compounds showed good FXa inhibitory activities, the potencies were a little lower than that of (RS)-1. From these results, it seems that 5-O-substitution is suitable for the linker structure between the indoline ring and the piperidine ring.
Next, we focused on the substituent attached to the nitrogen atom on the indoline ring and introduced various substituents other than the ethanesulfonyl group and examined their FXa inhibitory activities (Table 2) . Regarding the sulfonyl derivatives, both alkylsulfonyl compounds (10a, 10b) showed potent FXa inhibitory activities. Compound 10c with an aromatic ring also showed similar inhibitory activity to compounds 10a and 10b, though the activity was a slightly lower than (RS)-1. Then compounds with a polar functional group introduced into the terminal carbon chain moieties (10d, 11d) were synthesized. Both compounds showed potent FXa inhibitory activities superior to non-polar alkyl-or arylsulfonyl compounds. Furthermore, we studied the influence of the length of the alkylene between the sulfonamide group and the carboxyl group in 11d. Compounds 11e and 11f with longer carbon chains than that of 11d exhibited lower inhibitory activity than 11d. In these three compounds (11d-f), monomethylene compound 11d exhibited a favorable result. The introduction of an acyl group instead of a sulfonyl group exhibited similar or lower FXa inhibitory activities (10g vs. 10a and 11i vs. 11d). These results suggest that ethanesulfoyl ((RS)-1) and carboxymethysulfonyl (and its ester form) side chains are appropriate as substituents on the nitrogen atom.
Among the newly synthesized compounds, 11d showed more potent FXa inhibitory activity than (RS)-1. We attempted an acute toxicity test against these two compounds and 10d (an ester form of 11d) in mice. All the mice died immediately after administration of the compound (RS)-1 at 600 mg/kg (p.o.). This result suggests that the ethanesulfonyl compound (RS)-1 has a serious adverse reaction. On the other hand, all the mice survived with no lethal adverse reactions after administration of 10d or 11d (600 mg/kg, p.o., respectively). 23) This result indicates that the substituent on the nitrogen atom of the indoline ring is highly important not only for efficacy but also for safety. Among the above compounds, 10d and 11d with polar functional groups on the nitrogen atom showed favorable results in efficacy and safety.
We have reported that chiral compound (R)-1 showed more potent FXa inhibitory activity than the stereoisomer (S)-1. Based on this result, we synthesized the (R)-forms of 10d and 11d ((R)-10d and (R)-11d), to examine their inhibitory activities (Table 3 ). Both the two (R)-forms of 10d and 11d showed more potent inhibitory activities than their racemates. This result also suggests that the (R)-form is the active form. Moreover, the activity of carboxylic acid (R)-11d was superior to that of (R)-1. Therefore, (R)-11d is the best candidate of all the compounds described above.
We examined the effect of the in vitro anticoagulant activity of prothrombin time (PT) in hamster and human plasma. Table 4 shows the CT 2 values, the concentrations required to achieve 200% relative clotting time, of (R)-11d and (R)-1 in hamster and human plasma (in vitro). Between these two compounds, (R)-11d exhibited nearly equal or slightly more potent activity in both hamster and human plasma than that of (R)-1. In these in vitro tests, (R)-11d showed comparable activity to (R)-1 in FXa inhibition and anticoagulation.
We further evaluated the oral anticoagulant activity of (R)-11d. Table 5 shows the anticoagulant effect of (R)-11d in hamsters, marmosets and cynomolgus monkeys (ex vivo, p.o.). In each case, oral administration of (R)-11d prolonged the prothrombin time in a dose-dependent manner. In particular, administration to marmosets showed a highly potent anticoagulant effect. The CT 2 values, the dose required to achieve 200% relative clotting time, of (R)-11d against hamsters, marmosets and cynomolgus monkeys were 38, 6.9 and 18 mg/kg, respectively (ex vivo, 1 h). These results suggest that (R)-11d exhibited potent anticoagulant activity both in vitro and ex vivo.
In conclusion, we synthesized many indoline compounds and evaluated their FXa inhibitory activities. As a result, we found some novel N-sulfonylindoline derivatives with high FXa inhibitory activities. Among them, enantiomerically pure (R)-11d with carboxymethylsulfonyl group on the nitrogen atom exhibited potent anticoagulant activities both in vitro and ex vivo. Moreover, (R)-11d exhibited no lethal adverse reaction after oral administration in mice (600 mg/kg, p.o.). The substituent on the nitrogen atom of the indoline ring is important for efficacy and safety. Compound (R)-11d and some indoline derivatives are currently undergoing further evaluation and synthetic efforts to explore novel compounds having more potent FXa inhibitory activities and greater safety is underway. 8 mmol) in THF (110 ml) was added n-Bu 3 P (4.45 ml, 17.9 mmol) and ADDP (4.09 g, 16.2 mmol) in THF (40 ml) at 0°C and the mixture was stirred at room temperature for 1.5 h. The mixture was allowed to stand overnight, and the precipitate was filtered away. NH 4 Cl (100 ml) was added, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ11/9) to give 5d (4.85 g, 10.1 mmol, 93%) as an amorphous solid. (20 ml) , and the resulting mixture was stirred overnight at room temperature. To the reaction mixture were added DEAD (0.360 ml, 2.29 mmol), 7 (461 mg, 2.29 mmol) and PPh 3 (601 mg, 2.29 mmol), and the resulting mixture was stirred at room temperature for 2 h and stored overnight. H 2 O was added, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ3/2) to give 8d (1.11 g, 1.79 mmol, 78%) as an amorphous solid. Similarly, compounds 8a-c, 8e-g were prepared. thalen-2-yl)indolin-1-yl}-3-oxopropionate (8i) A solution of 1-(benzyloxycarbonyl)-5-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-2-(7-cyanonaphthalen-2-yl)indoline 8h (6.00 g, 9.94 mmol) in THF (30 ml) and EtOH (30 ml) was hydrogenated over 10% Pd-C (1.2 g) at room temperature for 4 h with stirring. The catalyst was filtered away, and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (CH 2 Cl 2 /EtOAcϭ20/1) to give 5-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-2-(7-cyanonaphthalen-2-yl)indoline (4.16 g, 8.86 mmol, 89%) as pale yellow crystals. This crystal (1.50 g, 3.19 mmol) was dissolved in CH 2 Cl 2 (20 ml) and treated with ethyl malonyl chloride (0.49 ml, 3.83 mmol) and pyridine (0.26 ml, 3.21 mmol) at Ϫ10°C. The resulting mixture was stirred at the same temperature for 2 h and at room temperature for 1 h. The reaction mixture was concentrated and to the resulting residue was added H 2 O. The mixture was extracted with EtOAc and washed with H 2 O and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ1/1) to give 8i (1.46 g, 2.50 mmol, 78%) as a pale yellow solid. 2-(7-cyanonaphthalen-2-yl)indolin-1-yl}sulfonyl)acetate 8d (790 mg, 1.27 mmol) in CH 2 Cl 2 (10 ml) and EtOH (10 ml) was bubbled hydrogen chloride under ice-cooling, and the resulting mixture was stirred at room temperature under tightly sealed condition for 3 h. The reaction mixture was concentrated. The resulting residue was dissolved in EtOH (15 ml) and the solution was treated with NH 4 Cl (123 mg, 2.30 mmol) in H 2 O (5 ml) and NH 3 solution (0.260 ml, 4.27 mmol). The mixture was allowed to stand at room temperature overnight and concentrated. The resulting residue was chromatographed on a silica gel column (Cosmosil 75C 18 -PREP TM , Nacalai Tesque Inc., MeCN/H 2 Oϭ3/97-1/9) to give the free base of 9d, (528 mg, 0.983 mmol, 77%) as an amorphous solid. This amorphous solid (49 mg, 0.091 mmol) was dissolved in EtOH (3 ml) and treated with a 4 N solution of hydrogen chloride in EtOAc (0.068 ml, 0.27 mmol). The mixture was concentrated and the resulting residue was dried at 70°C to give 9d (53 mg, 0.087 mmol) as an amorphous solid. (t-butoxycarbonyl) piperidin-4-yloxy]-2-(7-cyanonaphthalen-2-yl)indoline 8g (1.14 g, 2.23 mmol) in MeOH (20 ml) were added hydroxylamine hydrochloride (510 mg, 7.34 mmol) and Na 2 CO 3 (350 mg, 3.30 mmol), and the resulting mixture was stirred at 80°C for 12 h. The reaction mixture was concentrated and to the residue was added H 2 O. The resulting precipitate was filtered to give a colorless solid. This solid was dissolved in AcOH (20 ml) and treated with Ac 2 O (0.30 ml, 3.17 mmol). After stirring at room temperature for 20 min, the mixture was hydrogenated over 10% Pd-C (150 mg) at room temperature for 10 h while stirring. The catalyst was filtered away, and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (Chromatorex TM 'NH', Fuji Chemical Ltd., CH 2 Cl 2 /MeOHϭ9/1) to give the free base of 9g (843 mg, 1.97 mmol) as an amorphous solid. This amorphous solid was dissolved in EtOAc (25 ml) and treated with a 4 N solution of hydrogen chloride in EtOAc (10.6 ml, 42.4 mmol). The mixture was stirred at room temperature for 3 h and the resulting precipitate was filtered to give 9g (817 mg, 1.63 mmol, 73%) as an amorphous solid. in EtOH (12 ml) were added ethyl acetimidate hydrochloride (233 mg, 1.89 mmol) and Et 3 N (0.390 ml, 2.81 mmol). The resulting mixture was stirred at room temperature for 4 h and allowed to stand overnight. Ethyl acetimidate hydrochloride (106 mg, 0.858 mmol) and Et 3 N (0.24 ml, 1.73 mmol) were added, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated and the resulting residue was purified by preparative HPLC (TSK gel ODS-80Ts, Tosoh Corp., H 2 O/MeCNϭ9/1) to give the free base of 10d (325 mg, 0.563 mmol) as an amorphous solid. This amorphous solid (55 mg) was dissolved in EtOH (4 ml) and treated with a 4 N solution of hydrogen chloride in dioxane (0.071 ml, 0.284 mmol). The mixture was stored at room temperature for 5 min and concentrated. The resulting residue was dried overnight at 70°C to give 10d (60 mg, 0.092 mmol, 72%) as an amorphous solid.
Similarly, other bisamidine derivatives 10a-c, 10g were prepared. Similarly, other bisamidine derivatives 11e, 11f and 11i were prepared. t-Butyl 4-(3-Nitrophenoxy)piperidine-1-carboxylate (13) Diisopropyl azodicarboxylate (DIAD) (8.50 ml, 43.2 mmol) was added to a solution of 3-nitrophenol 12 (5.00 g, 35.9 mmol), 1-(t-butoxycarbonyl)-4-hydroxypiperidine 7 (8.68 g, 43.1 mmol) and PPh 3 (11.30 g, 43.1 mmol) in CH 2 Cl 2 (100 ml), and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated and the resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ17/3) to give 13 (9.72 g, 30.1 mmol, 84%) as a pale yellow oil. in THF (25 ml) was slowly added a solution of TBAF monohydrate (116 mg, 0.444 mmol) in THF (3 ml) and the mixture was stirred at Ϫ10°C for 0.5 h. TBAF (75% in H 2 O, 772 mg, 2.21 mmol) was then added and the mixture was stirred at room temperature for 1 h. NH 4 Cl solution was added, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ4/1-1/1) to give t-butyl 4-{2-[2-(7-cyanonaphthalen-2-yl)-2-hydroxyethyl]-3-nitrophenoxy}piperidine-1-carboxylate (1.29 g, 2.49 mmol, 56%) as a yellow amorphous solid. 1H, br s) .
5-{[1-(t-Butoxycarbonyl)piperidin-4-yl]methyl}-2-(7-cyanonaphthalen-2-yl)-1-(ethanesulfonyl)indoline (26)
To a solution of 9-borabicyclo[3.3.1]nonane (BBN) (0.4 M in THF, 5.4 ml, 2.2 mmol) was added 1-(t-butoxycarbonyl)-4-methylenepiperidine 25 (400 mg, 2.03 mmol) and the mixture was refluxed for 7 h. The resulting mixture was allowed to stand at room temperature overnight and 2-(7-cyanonaphthalen-2-yl)-1-(ethanesulfonyl)-5-{(trifluoromethanesulfonyl)oxy}indoline (739 mg, 1.45 mmol) in DMF (6 ml), PdCl 2 (dppf) · CH 2 Cl 2 (118 mg, 0.144 mmol) and K 2 CO 3 (301 mg, 2.18 mmol) in H 2 O (10 ml) were added. The mixture was stirred at 80°C for 5 h and the resulting mixture was poured into 1 N NaOH and extracted with EtOAc. The organic layer was washed with H 2 O and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ9/1-1/1) to give 26 (283 mg, 0.506 mmol, 35%) as a colorless oil. t-Butyl 4-(4-Nitroanilyl)piperidine-1-carboxylate (30) A solution of tbutyl 4-aminopiperidine-1-carboxylate 29 (10.0 g, 49.9 mmol) in DMA (100 ml) was treated with NaH (2.18 g, 50.0 mmol, as a 55% w/w dispersion in mineral oil) under cooling conditions and the mixture was stirred at 0°C for 15 min. Then a solution of 4-fluoro-1-nitrobenzene 28 (7.04 g, 49.9 mmol) in DMA (30 ml) was added and the mixture was stirred overnight at room temperature. H 2 O was added and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ9/1-3/2) to give 30 (7.86 g, 26.7 mmol, 95%) as a yellow solid. t-Butyl 4-(N-Methyl-4-nitroanilyl)piperidine-1-carboxylate (31) A solution of t-butyl 4-(4-nitroanilyl)piperidine-1-carboxylate 30 (100 mg, 0.311 mmol) in DMF (3 ml) was treated with NaH (15.0 mg, 0.344 mmol, as a 55% w/w dispersion in mineral oil) under cooling conditions and the mixture was stirred at room temperature for 15 min. Then MeI (0.020 ml, 0.32 mmol) was added and the mixture was stirred at room temperature for 1 h. NH 4 Cl solution was added and the mixture was extracted with EtOAc. The organic layer was washed with H 2 O and brine, dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ9/1-7/3) to give 31 (96.6 mg, 0.288 mmol, 93%) as a yellow solid. 
